Premium
Bioinversion of R ‐flurbiprofen to S ‐flurbiprofen at various dose levels in rat, mouse, and monkey
Author(s) -
Leipold Douglas D.,
Kantoci Darko,
Murray E. David,
Quiggle David D.,
Wechter William J.
Publication year - 2004
Publication title -
chirality
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.43
H-Index - 77
eISSN - 1520-636X
pISSN - 0899-0042
DOI - 10.1002/chir.20053
Subject(s) - flurbiprofen , chemistry , pharmacology , guinea pig , animal species , pharmacokinetics , animal model , dosing , experimental animal , medicine , biology , zoology , veterinary medicine
Information about the potential and extent of bioinversion of chiral drugs in laboratory animal species and humans is critical to the interpretation of preclinical pharm‐tox studies with these drugs. Unlike in the dog, guinea pig, and rabbit, in humans the 2‐arylpropionic acid (APA) R ‐flurbiprofen ( R ‐FB) undergoes very little bioinversion to S ‐flurbiprofen. The primary objective of this research was to identify laboratory animal species with an R ‐ to S ‐bioinversion profile similar to humans. Detailed evaluations of the pharmacokinetics parameters of R ‐flurbiprofen in male and female rats and mice, and male nude rats and monkeys demonstrated R ‐ to S ‐bioinversion of 30% (average) in monkeys, 15–24% in mice, and ∼4% in rats. To date, no laboratory animal species has been identified with an R ‐flurbiprofen bioinversion profile identical to humans. However, the rat has a bioinversion profile sufficiently similar to humans to be useful for preclinical pharm‐tox studies employing relatively short‐term dosing regimens. Chirality 16:379–387, 2004. © 2004 Wiley‐Liss, Inc.